PGF and hypertensive disorder: Although Thermo Fisher Scientific’s BRAHMS PlGF and sFlt-1 KRYPTOR tests along with Roche Diagnostics’ Elecsys sFlt-1/PlGF ratio tests have received U.S. FDA approval in May 2023 and February 2025, respectively, their FDA-approved intended use is quite restrictive, limited to hospitalized patients with hypertensive disorders for progression to PE with severe features within two weeks of presentation.